From the Editor's Desk

How to Regulate Generative AI in Health Care

A challenge confronting the Food and Drug Administration — and other regulators around the world — is how to regulate generative AI.  The approach it uses for new drugs and devices isn’t appropriate. Instead, the FDA should be conceiving of LLMs as novel forms of intelligence. It should employ similar approaches to those it applies to clinicians.

Continued here

TradeBriefs: Newsletters for Decision-Makers!